PH12015502088A1 - Novel compositions and processes for preparing 5-amino or substituted amino 1,2,3-triazoles and triazole orotate formulations - Google Patents
Novel compositions and processes for preparing 5-amino or substituted amino 1,2,3-triazoles and triazole orotate formulationsInfo
- Publication number
- PH12015502088A1 PH12015502088A1 PH12015502088A PH12015502088A PH12015502088A1 PH 12015502088 A1 PH12015502088 A1 PH 12015502088A1 PH 12015502088 A PH12015502088 A PH 12015502088A PH 12015502088 A PH12015502088 A PH 12015502088A PH 12015502088 A1 PH12015502088 A1 PH 12015502088A1
- Authority
- PH
- Philippines
- Prior art keywords
- amino
- processes
- triazoles
- formulations
- preparing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/557—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. orotic acid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
New polymorphs of 5-amino or substituted amino 1, 2, 3-triazole and substituted derivatives thereof, of orotates of the carboxyamidotriazoles, of formulations of the triazoles and orotic acid in the ratio of 1:1 to 1:4 (base:acid) and of safer processes of the preparation of the same are disclosed. The compounds are useful in the control and treatment of diseases including, but not limited to solid cancers, macular degeneration, retinopathy, chronic myeloid leukemia, AIDS and diseases which rely on aberrant signal transduction. The improved processes to prepare the orotate formulations use stable, efficient and safer starting azide intermediate materials in the synthesis of new polymorphs of carboxyamidotriazole.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US58444809A | 2009-09-04 | 2009-09-04 | |
| PCT/US2010/002430 WO2011028288A1 (en) | 2009-09-04 | 2010-09-03 | Novel compositions and processes for preparing 5-amino or substituted amino 1,2,3-triazoles and triazole orotate formulations |
| US12/807,415 US8377973B2 (en) | 2009-09-04 | 2010-09-03 | Compositions and processes for preparing 5-amino or substituted amino 1,2,3-triazoles and triazole orotate formulations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PH12015502088B1 PH12015502088B1 (en) | 2017-03-22 |
| PH12015502088A1 true PH12015502088A1 (en) | 2017-03-22 |
Family
ID=43648255
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12015502088A PH12015502088A1 (en) | 2009-09-04 | 2015-09-11 | Novel compositions and processes for preparing 5-amino or substituted amino 1,2,3-triazoles and triazole orotate formulations |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US8377973B2 (en) |
| EP (2) | EP2963023B1 (en) |
| JP (4) | JP2013503861A (en) |
| KR (1) | KR101597338B1 (en) |
| CN (2) | CN102595904B (en) |
| AP (1) | AP3345A (en) |
| AU (1) | AU2010290049B2 (en) |
| BR (1) | BR112012004539A2 (en) |
| CA (1) | CA2772075C (en) |
| CL (1) | CL2012000582A1 (en) |
| HK (1) | HK1212983A1 (en) |
| IL (1) | IL218430A0 (en) |
| MX (2) | MX2012002730A (en) |
| MY (1) | MY159430A (en) |
| NZ (2) | NZ598482A (en) |
| PH (1) | PH12015502088A1 (en) |
| RU (1) | RU2594155C2 (en) |
| SG (1) | SG178413A1 (en) |
| WO (1) | WO2011028288A1 (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8877785B2 (en) * | 2009-09-04 | 2014-11-04 | Tactical Therapeutics Inc | Methods and compositions for enhancing sensitivity of cytotoxic drugs with timely combinatorial therapy with carboxyamidotriazole orotate |
| US9089570B2 (en) * | 2010-09-03 | 2015-07-28 | Tactical Therapeutics Inc | Compositions for treating cancers having acquired resitance to prior chemotherapeutic and targeted drugs using carboxyamidotriazole orotate |
| US10378059B2 (en) * | 2013-08-02 | 2019-08-13 | Tactical Therapeutics, Inc. | Methods and molecular pharmacodynamic biomarkers for multiple signaling pathways in response to carboxyamidotriazole orotate |
| KR102623581B1 (en) * | 2016-07-18 | 2024-01-11 | 일동제약(주) | Orotic acid salt of antiviral agent, a method for preparing the salt and pharmaceutical composition comprising the salt |
| CN112083109B (en) * | 2019-07-08 | 2021-05-25 | 广东银珠医药科技有限公司 | Carboxyaminotriazole impurity and preparation method and detection method thereof |
| CN112358451B (en) * | 2021-01-11 | 2021-04-13 | 广东银珠医药科技有限公司 | Synthetic method of carboxyamidotriazole |
| CN113582935A (en) * | 2021-08-27 | 2021-11-02 | 中国医学科学院放射医学研究所 | Inflammatory corpuscle nucleotide-binding oligomerization domain-like receptor protein 3 inhibitor and preparation method and application thereof |
| CN113620892B (en) * | 2021-10-12 | 2022-02-22 | 广东银珠医药科技有限公司 | Carboxyaminotriazole single crystal, preparation method, composition and application thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2415740C2 (en) | 1974-04-01 | 1983-12-01 | Servomed Arznei GmbH & Co Pharma KG, 8000 München | Use of orotic acid in analgesic treatment with dextropropoxyphene, sodium salicylate or metamizole |
| US4590201A (en) | 1984-02-02 | 1986-05-20 | Merck & Co., Inc. | 5-amino or substituted amino 1,2,3-triazoles |
| US4847257A (en) * | 1987-08-20 | 1989-07-11 | Merck & Co., Inc. | 5-Amino or substituted amino 1,2,3,-triazoles useful as antiproliferative agents |
| JPH0356417A (en) * | 1989-05-08 | 1991-03-12 | Merck & Co Inc | 5-amino or substituted amino 1,2,3- triazoles useful as anti-transference agent |
| US5359078A (en) | 1989-05-19 | 1994-10-25 | The United States Of America As Represented By The Department Of Health And Human Services | Signal transduction inhibitor compounds |
| US5132315A (en) * | 1989-05-19 | 1992-07-21 | The United States Of America As Represented By The Department Of Health And Human Services | Therapeutic application of an anti-invasive compound |
| ATE278399T1 (en) | 1995-07-21 | 2004-10-15 | Savvipharm Inc | OROTATE SALTS OF 5-AMINO- OR SUBSTITUTED AMINO-1,2,3-TRIAZOLES FOR THE TREATMENT OF NEOPLASMS |
| US5728707A (en) * | 1995-07-21 | 1998-03-17 | Constantia Gruppe | Treatment and prevention of primary and metastatic neoplasms with salts of aminoimidazole carboxamide |
| TW403740B (en) * | 1997-06-10 | 2000-09-01 | Novartis Ag | Novel crystal modifications of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide |
| MXPA06013540A (en) * | 2004-05-25 | 2007-01-26 | Astrazeneca Ab | 3- (4- (2-dihydroisoxazol-3-ylpyridin-5-yl) phenyl) -5-triazol-1-ylmethyloxazolidin-2-one derivaives as mao inhibitors for the treatment of bacterial infections. |
| US8034823B2 (en) * | 2005-02-22 | 2011-10-11 | Savvipharm Inc | Method of increasing drug oral bioavailability and compositions of less toxic orotate salts |
| WO2009042694A1 (en) * | 2007-09-24 | 2009-04-02 | Comentis, Inc. | (3-hydroxy-4-amino-butan-2-yl) -3- (2-thiazol-2-yl-pyrrolidine-1-carbonyl) benzamide derivatives and related compounds as beta-secretase inhibitors for treating |
| US20150323994A1 (en) * | 2014-05-07 | 2015-11-12 | Immersion Corporation | Dynamic haptic effect modification |
| JP2017150532A (en) * | 2016-02-23 | 2017-08-31 | Ntn株式会社 | Rotation transmission device |
-
2010
- 2010-09-03 RU RU2012111454/04A patent/RU2594155C2/en active
- 2010-09-03 AU AU2010290049A patent/AU2010290049B2/en active Active
- 2010-09-03 AP AP2012006187A patent/AP3345A/en active
- 2010-09-03 CA CA2772075A patent/CA2772075C/en active Active
- 2010-09-03 CN CN201080050000.2A patent/CN102595904B/en active Active
- 2010-09-03 WO PCT/US2010/002430 patent/WO2011028288A1/en active Application Filing
- 2010-09-03 KR KR1020127008653A patent/KR101597338B1/en active IP Right Grant
- 2010-09-03 MY MYPI2012000629A patent/MY159430A/en unknown
- 2010-09-03 JP JP2012527868A patent/JP2013503861A/en active Pending
- 2010-09-03 SG SG2012010294A patent/SG178413A1/en unknown
- 2010-09-03 US US12/807,415 patent/US8377973B2/en active Active
- 2010-09-03 EP EP15178128.3A patent/EP2963023B1/en not_active Not-in-force
- 2010-09-03 MX MX2012002730A patent/MX2012002730A/en active IP Right Grant
- 2010-09-03 CN CN201510116934.6A patent/CN104817507A/en active Pending
- 2010-09-03 BR BR112012004539-3A patent/BR112012004539A2/en not_active Application Discontinuation
- 2010-09-03 NZ NZ598482A patent/NZ598482A/en unknown
- 2010-09-03 EP EP10814093.0A patent/EP2473051B1/en active Active
-
2012
- 2012-03-01 IL IL218430A patent/IL218430A0/en unknown
- 2012-03-02 CL CL2012000582A patent/CL2012000582A1/en unknown
- 2012-03-02 MX MX2014012090A patent/MX355198B/en unknown
-
2013
- 2013-02-27 NZ NZ624636A patent/NZ624636A/en unknown
-
2015
- 2015-09-11 PH PH12015502088A patent/PH12015502088A1/en unknown
- 2015-11-02 JP JP2015215891A patent/JP2016026213A/en active Pending
-
2016
- 2016-01-29 HK HK16101046.4A patent/HK1212983A1/en unknown
-
2017
- 2017-08-03 JP JP2017150532A patent/JP2017203038A/en active Pending
-
2020
- 2020-01-31 JP JP2020014827A patent/JP2020105178A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12015502088A1 (en) | Novel compositions and processes for preparing 5-amino or substituted amino 1,2,3-triazoles and triazole orotate formulations | |
| CA3118330A1 (en) | Inhibitors of cyclin-dependent kinase 7 (cdk7) | |
| ES2968809T3 (en) | Dihydroorotate dehydrogenase inhibitors | |
| MY150059A (en) | Pyrrolo [2,3-d] pyrimidin derivatives as protein kinase b inhibitors | |
| WO2009007390A3 (en) | 2-pyraz inylbenz imidazole derivatives as receptor tyrosine kinase inhibitors | |
| TW200635899A (en) | Chemical compounds | |
| IL190654A (en) | Methylsulfonamido-phenyl-propanamide derivatives, processes for their preparation and medicaments containing them | |
| PL1756086T3 (en) | Pyridin-4-yl-ethynyl-imidazoles and pyrazoles as mglu5 receptor antagonists | |
| TN2010000040A1 (en) | 2-3-7-substituted imidazo - [1-2b] pyridazines for treatment of alk 4 or alk 5 mediated diseases | |
| NZ701440A (en) | Pyrazole derivatives as jak inhibitors | |
| IL176547A0 (en) | 1,3,5-trisubstituted 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity | |
| WO2006015860A3 (en) | Pyrazole derivatives for treating conditions mediated by activation of the adenosine a2b or a3 receptor | |
| EP3822263A1 (en) | Biaryl ether-type quinazoline derivative | |
| US20220289732A1 (en) | Heterocyclic wdr5 inhibitors as anti-cancer compounds | |
| EA006244B1 (en) | 2-amino-2-alkyl-5-heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors | |
| GB0513886D0 (en) | Novel compounds | |
| Chojnacki et al. | Synthesis, in vitro antiproliferative activity and kinase profile of new benzimidazole and benzotriazole derivatives | |
| WO2007013096A8 (en) | Improved process for the preparation of 2r, 3s-2-(2,4-difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1h-1,2,4-triazol-1-yl) butan-2-ol (voriconazole) | |
| UA88910C2 (en) | Heterocyclic compounds for treatment or reduction of diseases associated with the cannabinoid receptor and processes for the preparation thereof | |
| UY37222A (en) | PROCEDURE FOR THE PREPARATION OF DERIVATIVES OF 1-PHENYL-1,2,4-TRIAZOL REPLACED BY 5-HYDROXYALQUYL | |
| UA106217C2 (en) | Synthesis of and salt forms of (r)-3-((e)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine | |
| CA3159211A1 (en) | Fluorinated quinoline, quinoxaline and benzo[b][1,4]oxazine derivatives as dihydroorotate dehydrogenase (dhodh) inhibitors for the treatment of cancer, autoimmune and inflammatory diseases | |
| WO2008075163A3 (en) | An improved process for the preparation of rizatriptan | |
| NZ613333A (en) | Derivatives of glyco-cf2-serine and glyco-cf2-threonine | |
| WO2009037244A3 (en) | 5-aryl-4,5-dihydro-(1h)-pyrazoles as cannabinoid cb1 receptor agonists |